Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Lung function in children and adolescents with juvenile idiopathic arthritis during long-term treatment with methotrexate: a retrospective study.

Leiskau C, Thon A, Gappa M, Dressler F.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):302-7. Epub 2012 Apr 13.

PMID:
22409955
2.

Lung function and diffusing capacity for carbon monoxide in patients with juvenile chronic arthritis: effect of disease activity and low dose methotrexate therapy.

Pelucchi A, Lomater C, Gerloni V, Foresi A, Fantini F, Marazzini L.

Clin Exp Rheumatol. 1994 Nov-Dec;12(6):675-9.

PMID:
7895405
3.

Assessment of cardiac and pulmonary function in children with juvenile idiopathic arthritis.

Alkady EA, Helmy HA, Mohamed-Hussein AA.

Rheumatol Int. 2012 Jan;32(1):39-46. doi: 10.1007/s00296-010-1548-5. Epub 2010 Jul 24.

PMID:
20658239
4.

Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.

Kostik MM, Gaidar EV, Hynnes AY, Dubko MF, Masalova VV, Snegireva LS, Chikova IA, Isupova EA, Nikitina TN, Serogodskaya ED, Kalashnikova OV, Ravelli A, Chasnyk VG.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):714-8. Epub 2016 Jun 22.

PMID:
27385618
5.

Effect on lung function of methotrexate and non-steroid anti-inflammatory drugs in children with juvenile rheumatoid arthritis.

Camiciottoli G, Trapani S, Castellani W, Ginanni R, Ermini M, Falcini F.

Rheumatol Int. 1998;18(1):11-6.

PMID:
9672993
6.

Pulmonary function in children with juvenile idiopathic arthritis and effects of methotrexate therapy.

Schmeling H, Stephan V, Burdach S, Horneff G.

Z Rheumatol. 2002 Apr;61(2):168-72.

PMID:
12056294
7.

Pulmonary function in patients receiving long-term low-dose methotrexate.

Cottin V, Tébib J, Massonnet B, Souquet PJ, Bernard JP.

Chest. 1996 Apr;109(4):933-8.

PMID:
8635373
8.

Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.

van Dijkhuizen EH, Bulatović Ćalasan M, Pluijm SM, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, Wulffraat NM.

Pediatr Rheumatol Online J. 2015 Feb 18;13:5. doi: 10.1186/s12969-015-0002-3. eCollection 2015.

9.

Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study.

van Dijkhuizen EH, Pouw JN, Scheuern A, Hügle B, Hardt S, Ganser G, Kümmerle-Deschner JB, Horneff G, Holzinger D, Bulatović Ćalasan M, Wulffraat NM.

Clin Exp Rheumatol. 2016 Jan-Feb;34(1):148-54. Epub 2016 Feb 2.

PMID:
26843067
10.

Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.

Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J.

Arthritis Care Res (Hoboken). 2016 Jan;68(1):46-54. doi: 10.1002/acr.22649.

11.

Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.

Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2009 Sep;60(9):2794-804. doi: 10.1002/art.24777.

12.

The experience of taking methotrexate for juvenile idiopathic arthritis: results of a cross-sectional survey with children and young people.

Mulligan K, Wedderburn LR, Newman S.

Pediatr Rheumatol Online J. 2015 Dec 12;13:58. doi: 10.1186/s12969-015-0052-6.

13.
14.

Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.

Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC.

Arthritis Res Ther. 2015 Oct 22;17:295. doi: 10.1186/s13075-015-0814-z.

15.

Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study.

van der Meer A, Wulffraat NM, Prakken BJ, Gijsbers B, Rademaker CM, Sinnema G.

Clin Exp Rheumatol. 2007 May-Jun;25(3):480-5.

PMID:
17631750
16.

Juvenile idiopathic arthritis in adulthood and orthopaedic intervention.

Malviya A, Johnson-Lynn S, Avery P, Deehan D, Foster H.

Clin Rheumatol. 2009 Dec;28(12):1411-7. doi: 10.1007/s10067-009-1266-0. Epub 2009 Aug 30.

PMID:
19727915
17.

Pulmonary function in rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study.

Beyeler C, Jordi B, Gerber NJ, Im Hof V.

Br J Rheumatol. 1996 May;35(5):446-52.

PMID:
8646435
18.

Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis.

Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM.

J Pediatr. 1992 Mar;120(3):468-73.

PMID:
1538301
19.

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).

Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K.

Ann Rheum Dis. 2016 May;75(5):855-61. doi: 10.1136/annrheumdis-annrheumdis-2014-206747. Epub 2015 Apr 29.

PMID:
25926155
20.

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review.

van Dijkhuizen EH, Wulffraat NM.

Pediatr Rheumatol Online J. 2014 Dec 11;12:51. doi: 10.1186/1546-0096-12-51. eCollection 2014. Review.

Supplemental Content

Support Center